Skip to content

RCT Comparing 19Ga vs 22Ga EBUS-TBNA Needles in Carcinoma.

Randomized Controlled Trial Comparing the Performance of 19 Gauge Versus 22 Gauge EBUS-TBNA Needles in Lung Carcinoma

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02906280
Enrollment
78
Registered
2016-09-20
Start date
2016-05-31
Completion date
2017-12-31
Last updated
2016-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasm

Keywords

EBUS-TBNA

Brief summary

EBUS-TBNA is often the sole diagnostic test applied in patients with stage IV lung cancer. A limitation of the TBNA needle when using a 22 Gauge needle is the limited ability to procure adequate histological samples. Although a larger 19 Ga needle can procure histological samples as demonstrated by the conventional 19 Ga needle, published data are not existing with respect to molecular diagnostics. A new nitinol-based 19 Ga needle has been developed for EBUS-TBNA. Given the frequent usage of 22 Ga needles for molecular diagnostics and the recent technical advancements in 19 Ga needle technology, we conduct a RCT to compare the performance of both needle types.

Detailed description

All patients with (suspected) stage IV lung carcinoma identified on spiral computed tomography scan and requiring an EBUS-TBNA investigation to obtain intrathoracic hilar or mediastinal lymph node tissue for diagnosis, subtyping and genotyping of lung cancer are eligible for participation in this study. Procedural technique : patients undergo an EBUS-TBNA procedure with either the Flex 19 Ga needle or the 22 Ga needle ; all procedures are performed using a linear array echoendosope under moderate sedation (standard practice). Primary endpoint of the study is the presence of core tissue that is defined as a continuous string of material as observed on the microscopic examination. Secondary endpoints are elements relevant to molecular analysis.

Interventions

DEVICEEBUS-TBNA needle

tissue sampling

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* (suspected) stage IV lung carcinoma identified on spiral computed tomography scan * requiring an EBUS-TBNA investigation to obtain intrathoracic hilar or mediastinal lymph node tissue for diagnosis

Exclusion criteria

* uncontrolled coagulopathy * tracheal stenosis

Design outcomes

Primary

MeasureTime frameDescription
Tissue core14 monthsDescriptive tissue characteristics of tumor sample

Secondary

MeasureTime frameDescription
Tumor cellularity per area of diagnostic tissue14 monthsObjective pathologic measurement of tumor density
Quantity of DNA extracted14 monthsObjective measurement of the amount of DNA
Success rate of Next Generation Sequencing14 monthsFeasibility of NGS testing

Countries

Belgium

Contacts

Primary ContactChristophe Dooms
christophe.dooms@uzleuven.be

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026